RAVULIZUMAB
ravulizumab 300 mg/3 mL injection, 3 mL vial
RAVULIZUMAB (12841W)
12841W
Manner of administration:Injection
Restriction
Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Initial treatment - Initial 1 (new patient) induction dose
Restriction
Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Initial treatment - Initial 2 (switch from LSDP eculizumab) induction dose
Restriction
Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Return from PBS-subsidised eculizumab - induction dose
Restriction
Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
Treatment phase: Switching from PBS-subsidised pegcetacoplan or iptacopan - induction doses
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $6,623.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ultomiris | |||||